导读： 为了规范和加强实验室生物安全监管，6月11日，国家卫健委发布了修订后的新版《人间传染的高致病性病原微生物实验活动审批管理办法》。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 | 为了规范和加强实验室生物安全监管，6月11日，国家卫健委发布了修订后的新版《人间传染的高致病性病原微生物实验活动审批管理办法》 | | --- | 《管理办法》包括四章，共二十五条。第一章总则，规定《管理办法》制定原则、适用范围、各方职责等。第二章实验活动的审批，主要明确 了申请条件、申请材料、审批程序及批准部门等内容。第三章管理与监督，主要明确了实验室的设立单位及其主管部门、各级卫生健康主管部 门监管职责、监管方式、监督检查等内容，并进一步明确了对于违反本《管理办法》行为相关的法律责任。全文如下： （以下简称《管理办法》）。 中华人民共和国国家卫生健康委员会令 第 14 号 《人间传染的高致病性病原微生物实验活动审批管理 办法》已经 2025年3月31日第1次委务会议审议通过,现 予公布,自 2025年7月1日起施行。 主 任 雷海潮 2025年 4月 ...

Core Viewpoint - The article highlights the launch of three chromatography instruments by Haikejing Medical Technology, a subsidiary of Haomuxing, which enhances domestic capabilities in high-end analytical instruments and provides advanced detection solutions for various industries including clinical diagnostics, environmental monitoring, and food safety [2][4]. Group 1: Product Launch - Haikejing Medical Technology has officially launched three core products: the two-dimensional liquid chromatography instrument, H-1000 liquid chromatography instrument, and H-5000 ion chromatography instrument, marking a significant advancement in China's self-developed high-end analytical instruments [2][3]. - The H-1000 liquid chromatography instrument features an advanced fluid control system and intelligent operation platform, offering high sensitivity, high repeatability, and rapid analysis capabilities, suitable for environmental monitoring and food testing [3]. - The two-dimensional liquid chromatography instrument significantly improves separation efficiency and analytical capability for complex samples, particularly beneficial for clinical in vitro diagnostics such as drug concentration testing [4]. - The H-5000 ion chromatography instrument is characterized by high precision and low detection limits, effectively quantifying anions and cations in environmental water quality, food additives, and pharmaceuticals, aiding in industry compliance monitoring [6]. Group 2: Technological Innovation - The three chromatography instruments have achieved domestic substitution of key components, enhancing industry autonomy. The two-dimensional liquid chromatography instrument employs a three-pump series flow path design and intelligent gradient control technology, significantly improving analytical efficiency [8]. - The ion chromatography instrument utilizes a high-performance, low-pulse PEEK dual-piston constant flow pump, along with a high-precision stepper motor-driven precision ball screw system, enhancing performance, reliability, stability, and durability [8]. Group 3: Future Development and Collaboration - The successful development of these chromatography instruments is a key achievement in the company's strategy of "technology as the core, application as the foundation." The company plans to increase R&D investment and expand applications in life sciences, environmental monitoring, and new materials [9]. - Haikejing Medical Technology has established cooperation intentions with several renowned universities and third-party testing institutions, with some products entering the stage of large-scale production [9].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，南京大学发布16项仪器设备采购意向，预算总额达9015万元，涉及三通道波长可调谐飞秒激光器、可旋转高磁 场 稀 释 制 冷 机 、 原 子 层 刻 蚀 （ ALE ） 设 备 、 半 导 体 电 子 测 量 系 统 、 超 导 量 子 干 涉 磁 学 测 量 系 统 等 ， 预 计 采 购 时 间 为 2025年5~9月。 | 采购 | 需求概况 | 预算 | 采购 | | --- | --- | --- | --- | | 项目 | | 万元 | 时间 | | 三通道波 | 南京大学拟采购三通道波长可调谐飞秒激光器一台，主要应用于凝聚态超快动力学，分子动力学，超快光学，阿秒光学等领域。主要 | | 202 | | 长可调谐 | 采购需求如下：波长调谐范围：680–1300nm；输出功率：＞3W@920nm；脉冲宽度：＜160fs；重复频率：78MHz；光束指向 | 160 | 5 年 | | 飞秒激光 | 稳定性：＜200μrad；光束质量 M2：＜1.2；飞秒激光具有超快的时间分辨能 ...

导读： 6项新国标将实施，公共场所卫生标准升级，新增9类健康指标检测，涵盖空气流通、有害物质、病菌防控等，提升公共场所卫 生安全。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近 日 ， 市 场 监 管 总 局 （ 国 家 标 准 委 ） 批 准 发 布 《 公 共 场 所 卫 生 检 验 方 法 第 1 部 分 ： 物 理 性 指 标 》 （ GB/T18204.1— 2025）等6项国家标准。该系列标准由国家疾控局组织修订，将于2025年12月1日起正式实施。 近年来，公共场所卫生安全受到社会广泛关注，为贯彻落实《健康中国行动（2019—2030年）》提出的"建设健康环 境"有关要求，本次标准修订重点解决大家关心的商场、泳池、酒店等场所卫生安全问题，主要有三大变化： 一是检测项目更全面，新增9类健康指标检测，包括新风量和自然采光系数等空气流通方面指标，甲醛、PM2.5、放射 性气体氡等有害物质限量指标，泳池水消毒效果、军团菌（可能引发严重肺炎的细菌）、β-溶血性链球菌（常见致病 菌）等病菌防控相关指标。 二是检测技术更先进，升级了用 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，山西省大气探测技术保障中心发布4项仪器设备采购意向，预算总额达1.89亿元，涉及无人机试验平台、双波长 四通道拉曼激光雷达、冰核采样与分析设备、二维成像降水粒子谱仪、微雨雷达、全天空成像仪、冰雹自动测量设备、 雹雨分测仪、GPS火箭气象探空系统、冰雹微物理结构分析实验室等，预计采购时间为2025年6~10月。 山西省大气探测技术保障中心 2025年6~10月 仪器设备采购 意向汇总表 | | | | 采 | | --- | --- | --- | --- | | | | 预算 | 购 | | 采购项目 | 需求概况 | 万元 | 时 | | | | | 间 | | | | | 202 | | | | | 5 | | 华北区域人工影响天气能力建设项目 | 国家作业飞机及机载大气探测子系统、机载催化作业子系统、空地通信子系统及空地综合业务系统联调 | 15634 | 年 | | （山西）-综合作业能力建设采购项目 | 测试。 | | 6 | | | | | 月 | | | | | 202 | ...

Core Viewpoint - XtalPi Holdings Limited has completed the acquisition of Liverpool ChiroChem, enhancing its capabilities in AI-driven autonomous experimental platforms for chemical exploration, which will better serve clients in drug development, new materials discovery, and high-value chemicals [2][4]. Group 1: Acquisition Details - The acquisition of Liverpool ChiroChem (LCC) will strengthen XtalPi's "AI + Robotics" platform in the chemical exploration domain [2]. - LCC's founder, Dr. Paul Colbon, expressed excitement about leveraging AI and robotics to explore a broader chemical space and expedite the discovery of high-value molecules [4]. - LCC, established in 2014, focuses on the design and synthesis of novel chiral molecules and has developed the PACE technology platform, which integrates AI software with automation for efficient molecular screening and synthesis [4][5]. Group 2: Technological Synergy - LCC possesses a leading global database of chiral chemical entities, providing high-quality data support for AI models in chiral molecular exploration [5]. - The collaboration between XtalPi and LCC will enhance capabilities in high-throughput and micro-scale molecular library construction, complementing XtalPi's large-scale molecular library technology [5]. - XtalPi continues to enhance its technical strength in chemical exploration through strategic partnerships, incubation, joint research, and acquisitions [5]. Group 3: Company Background - XtalPi was founded in 2015 by three physicists from MIT and operates as an innovative R&D platform powered by quantum physics, AI, and robotics [6]. - The company provides drug and materials science R&D solutions for global and domestic companies across various industries, including pharmaceuticals, agricultural technology, energy, and new chemicals [6].

导读： 近日，清华大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出22项仪器设备采购意向，预算 总额达1.48亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，清华大学发2 2项仪器设备采购意向，预算总额达1 . 4 8亿元，涉及光谱仪总装、激光闪光光解光谱仪、台式X射线 吸收精细结构谱仪、共聚焦污染物毒性分析仪、多功能酶标仪、荧光定量核酸扩增仪等，预计采购时间为2 0 2 5年6~9 月。 | | | | 采 | | --- | --- | --- | --- | | 采购 | 需求概况 | 预算 | 购 | | 项目 | | 万元 | 时 | | | | | 间 | | | | | 202 | | 光谱仪总 | | | 5 | | 装 | 光谱仪总装 | 10000 | 年 | | | | | 6 月 | | | | | 202 | | 智能驾驶 | | | 5 | | 仿真系统 | 智能驾驶仿真系统 | 125 | 年 | | | | | 9 | | | | | 月 | | | | | 202 | ...

Core Insights - The global scientific instrument industry reported a total net profit of 19.8 billion yuan from 21 listed companies in 2024, showing a slight decline year-on-year, with the average net profit margin dropping to 11.6% from 15.7% in 2023, indicating a slowdown in industry growth and increasing strategic differentiation among companies [1][2]. Group 1: Financial Performance - The top three companies maintained their positions, with Thermo Fisher leading with a net profit of 6.33 billion USD, a profit margin of 14.8%, driven by a decrease in sales costs and an increase in gross profit margin [5]. - Danaher and Merck, while retaining their second and third positions, faced challenges with Danaher's net profit declining for two consecutive years due to a drop in the biotechnology segment, while Merck managed a slight profit decrease of 1.7% through market expansion in emerging regions [5][6]. - Among the 21 companies, 10 had net profit margins significantly above the industry average of 11.6%, highlighting the profitability efficiency of leading firms [8]. Group 2: Strategic Adjustments - Companies like SIBAT and Sartorius showed remarkable performance, with SIBAT achieving a 60.79% increase in net profit despite a 10% revenue decline, demonstrating effective cost control strategies [6]. - Sartorius experienced a 46.1% increase in net profit, attributed to a 16% revenue growth in the North American market and strategic focus on energy measurement [6]. - Agilent, despite a slight revenue decline, successfully implemented cost reduction strategies, resulting in a record high net profit and an improved global ranking [6]. Group 3: Challenges and Market Dynamics - Nine companies, including Zeiss and Veralto, faced profit declines despite revenue growth due to factors like currency fluctuations and rising costs [9]. - Companies such as Illumina and Bio-Rad encountered dual declines in revenue and profit, with Illumina suffering from goodwill impairment and Bio-Rad facing increased restructuring costs [9]. - The industry is experiencing structural adjustments, with emerging markets like Latin America and the Middle East driving growth for some companies, while the Chinese market presents challenges [10]. Group 4: Future Outlook - The ability of Thermo Fisher to return to peak profitability, the effectiveness of Danaher's cost-saving initiatives, and Sartorius's growth potential in energy measurement will be key indicators for the industry's direction [10]. - Companies must address the challenge of achieving sustainable growth through technological innovation, market rebalancing, and operational efficiency amidst overall profit margin pressures [10].

Core Viewpoint - The article highlights the procurement intentions of Central South University’s innovation platform, with a total budget of 191.579 million yuan for various advanced scientific instruments, expected to be purchased between July and December 2025 [1][2]. Procurement Overview - The procurement includes a range of sophisticated instruments such as: - Ultraviolet-visible near-infrared quantum efficiency tester (112.86 million yuan) [3] - Three-dimensional reconstruction focused ion beam electron microscope (1.3 billion yuan) [4] - High-sensitivity photoelectric and electro-optical conversion quantum efficiency tester (980 million yuan) [4] - Energy loss tester (283 million yuan) [4] - Various testing machines for mechanical properties, including high-temperature creep relaxation testing machines and electronic fatigue testing machines [3][4]. Budget Allocation - The total budget of 191.579 million yuan is allocated across multiple projects, with significant amounts dedicated to: - High-temperature and low-temperature testing equipment [3][4] - Advanced imaging systems such as X-ray fluorescence spectrometers and electron microscopes [4][5]. Expected Procurement Timeline - The expected procurement period is set for July to December 2025, indicating a strategic planning phase for the university's research capabilities [2][3]. Instrument Specifications - Specific instruments listed for procurement include: - Multi-field coupled low-field nuclear magnetic imaging system (450 million yuan) [4] - Soft X-ray electron probe analysis system (800 million yuan) [5] - Glow discharge mass spectrometer (970 million yuan) [5]. Conclusion - The procurement initiative reflects Central South University's commitment to enhancing its research infrastructure through significant investments in advanced scientific instruments, which may present opportunities for suppliers and manufacturers in the scientific equipment sector [1][2].

Core Viewpoint - The article emphasizes the growing importance of mass spectrometry technology in clinical diagnostics, driven by the need for earlier detection, more precise diagnosis, and comprehensive evaluation in the context of precision medicine and individualized treatment [1]. Group 1: Industry Trends - The trend in clinical diagnostics is moving towards "earlier detection, more precise diagnosis, and comprehensive evaluation," which aligns with the advancements in precision medicine [1]. - Mass spectrometry is recognized for its high sensitivity, specificity, and capability for simultaneous detection of multiple components, making it a key technology in the transformation of clinical testing [1]. Group 2: Clinical Applications - Mass spectrometry has been widely applied for the precise detection of small molecules and is gradually expanding into the detection of larger biomolecules such as proteins, peptides, and nucleic acids [1]. - The technology supports early disease screening, subtype diagnosis, and efficacy evaluation, providing reliable technical support for clinical applications [1]. Group 3: Upcoming Event - A network seminar titled "Fourth Clinical Mass Spectrometry Technology and Application Progress" is scheduled for June 12, 2025, organized by Instrument Information Network, to discuss the future development paths of clinical mass spectrometry [2][3].